By identifying differences in immune cell subtypes (e.g., CD8+ T and NK&T cells) following BCL9 modulation and CD155-CD226 as a potential checkpoint, our data will certainly help CRC diagnosis and therapy. The gene discussed is BCL9; the disease is colorectal carcinoma.